Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the treatment outcome of unresectable soft tissue sarcoma using response based treatment

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard; Liposomal doxorubicin; Melphalan; Thiotepa

Criteria

Inclusion Criteria:

• Patients with unresectable localized high grade soft tissue sarcoma

Exclusion Criteria:

• Patients with organ dysfunction (ejection fraction, liver function test, creatinine > CTCAE grade 2)